Amarin Posts First Profitable Quarter in Over Two Years; Cash Rises to $323.4M
AMRN is trading near its 52-week low of $11.25 (6.2% above the low).
Summary
Amarin reported a $0.2M net profit for Q3 2026 — its first in over two years — as operating expenses fell 44%. Cash rose to $323.4M with no debt. Revenue still declined 20% to $39.6M, however, as U.S. VASCEPA sales slid 30% on generic competition.
Key Events · Earnings and Guidance · AMRN
-
First Profitable Quarter in Over Two Years
Q3 2026 net income was $0.2M versus a $7.7M net loss in Q3 2025, a 103% swing, as operating expenses fell 44% to $18.5M.
-
Revenue Still Declining
Total net revenue fell 20% to $39.6M; U.S. product revenue dropped 30% to $28.5M on lower net pricing from generic competition, partly offset by licensing and royalty revenue up 139% to $2.7M.
-
Cash Build and Debt-Free Balance Sheet
Cash, cash equivalents and short-term investments reached $323.4M at September 30, 2026, up from $314.6M at Q2, with $9.2M of operating cash flow and zero debt.
-
Barclays Strategic Review Continues
Management said it continues to work closely with Barclays, its exclusive financial advisor, on efforts to maximize shareholder value, with no timeline given.
Analysis · AMRN · Life Sciences
The headline profit is less about growth than about cost discipline: a 44% cut in operating expenses to $18.5M turned a $7.7M loss a year earlier into a $0.2M net profit in Q3 2026. Revenue still fell 20% to $39.6M, with U.S. VASCEPA sales down 30% on generic pricing pressure. The balance sheet is the real story. Cash and short-term investments reached $323.4M, the company carries no debt, and operating cash flow was positive for a fourth straight quarter at $9.2M — all of which buys time. Management also confirmed it is still working with Barclays on strategic alternatives, so the profit and the cash pile matter mainly as negotiating leverage in that process.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 30.5% of the 1494 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.03%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AMRN was trading at $11.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $252.4M. The 52-week trading range was $11.25 to $20.57. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.